Flexion Therapeutics Inc Net Income per Employee (FLXN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Flexion Therapeutics Inc   (NASDAQ: FLXN)
 

Flexion Therapeutics Inc Net Income per Employee

FLXN's Quarterly Results, Trends, Rankings, Statistics
Flexion Therapeutics Inc recorded a cumulative net loss of $-101 million during 12 month ending in the third quarter 2021.
The Healthcare sector has seen employees of 189 other companies achieving higher income per employee. While Flexion Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3677.


What is Income per Employee Ratio?






FLXN Net Income per Employee (Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -468,479 -442,088 -490,512 -528,865 -593,372
FLXN's Total Ranking # 3677 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


FLXN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 190
Healthcare Sector # 526
Overall Market # 3677

Net Income per Employee Statistics
High Average Low
$ -290,004 $ -597,165 $ -835,433
(Sep 30 2016)   (Sep 30 2018)







Companies with similar Income per Employee for 12 month ending Sep 30 2021, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2021Number of Employees Sep 30 2021


Date modified: 2026-08-29T17:23:57+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.